Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530887 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL3530890 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL3532566 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL3532567 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL4635927 | 0.84 | MAPT (0.44) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL4635932 | 0.84 | MAPT (0.44) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL3531827 | 0.83 | ALDH1A1 (0.42) | ALDH1A1KMT2AHTTPOLBMAPT | |
| SCHEMBL3530886 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KMT2APOLBMAPTMEN1 | |
| SCHEMBL3534757 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KMT2AATMHTTPOLB | |
| SCHEMBL3531657 | 0.77 | KMT2A (0.50) | ALDH1A1KMT2AATMHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | ALDH1A1 690/4885KMT2A 2512/4885ATM 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.